Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L McCaleb

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Plos One|August 8, 2013
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese miceXing Xian Yu, Lynnetta M Watts, Vara Prasad Manchem, et al.
Rare Diseases (Austin, Tex.)|July 24, 2014
Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung diseaseShuling Guo, Sheri L Booten, Andrew Watt, et al.
Molecular Vision|September 1, 2017
Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotideTamar R Grossman, Michele Carrer, Lijiang Shen, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Immunobiology|August 27, 2015
Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in miceTamar R Grossman, Lisa A Hettrick, Robert B Johnson, et al.
Immunobiology|February 2, 2025
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with SefaxersenMichael L McCaleb, Steven G Hughes, Tamar R Grossman, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
The Journal of Clinical Investigation|December 21, 2013
Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in miceShuling Guo, Sheri L Booten, Mariam Aghajan, et al.
Investigative Ophthalmology & Visual Science|October 6, 2015
Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell DegenerationSusan F Murray, Ali Jazayeri, Michael T Matthes, et al.
Journal of Hepatology|December 15, 2015
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotidesGaetan Billioud, Robert L Kruse, Melissa Carrillo, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Plos One|August 8, 2013
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese miceXing Xian Yu, Lynnetta M Watts, Vara Prasad Manchem, et al.
Rare Diseases (Austin, Tex.)|July 24, 2014
Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung diseaseShuling Guo, Sheri L Booten, Andrew Watt, et al.
Molecular Vision|September 1, 2017
Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotideTamar R Grossman, Michele Carrer, Lijiang Shen, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Immunobiology|August 27, 2015
Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in miceTamar R Grossman, Lisa A Hettrick, Robert B Johnson, et al.
Immunobiology|February 2, 2025
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with SefaxersenMichael L McCaleb, Steven G Hughes, Tamar R Grossman, et al.
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
The Journal of Clinical Investigation|December 21, 2013
Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in miceShuling Guo, Sheri L Booten, Mariam Aghajan, et al.
Investigative Ophthalmology & Visual Science|October 6, 2015
Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell DegenerationSusan F Murray, Ali Jazayeri, Michael T Matthes, et al.
Journal of Hepatology|December 15, 2015
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotidesGaetan Billioud, Robert L Kruse, Melissa Carrillo, et al.
Pageof 2